Allo-reactive T cells for the treatment of hematological malignancies.

Abstract:

:Several mechanisms can be responsible for control of hematological tumors by allo-reactive T cells. Following allogeneic stem cell transplantation (alloSCT) donor T cells recognizing genetic disparities presented on recipient cells and not on donor cells are main effectors of tumor control, but also of the detrimental graft versus host disease (GVHD). Since after transplantation normal hematopoiesis is of donor origin, any T cell response directed against polymorphic antigens expressed on hematopoietic recipient cells but not on donor cells will result in an anti-tumor response not affecting normal hematopoiesis. After fully HLA-matched alloSCT, T cells recognizing polymorphic peptides derived from proteins encoded by genes selectively expressed in hematopoietic lineages may result in anti-tumor responses without GVHD. Due to the high susceptibility of hematopoietic cells for T cell recognition, a low amplitude of the overall T cell response may also be in favor of the anti-tumor reactivity in hematological malignancies. A mismatch between donor and patient for specific HLA-alleles can also be exploited to induce a selective T cell response against patient (malignant) hematopoietic cells. If restricting HLA class II molecules are selectively expressed on hematopoietic cells under non-inflammatory circumstances, allo HLA class-II responses may control the tumor with limited risk of GVHD. Alternatively, T cells recognizing hematopoiesis-restricted antigens presented in the context of mismatched HLA alleles may be used to treat patients with hematological cancers. This review discusses various ways to manipulate the allo-immune response aiming to exploit the powerful ability of allo-reactive T-cells to control the malignancies without causing severe damage to non-hematopoietic tissues.

journal_name

Mol Oncol

journal_title

Molecular oncology

authors

Falkenburg JH,Jedema I

doi

10.1016/j.molonc.2015.10.014

subject

Has Abstract

pub_date

2015-12-01 00:00:00

pages

1894-903

issue

10

eissn

1574-7891

issn

1878-0261

pii

S1574-7891(15)00192-1

journal_volume

9

pub_type

杂志文章,评审
  • Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts.

    abstract::Bone morphogenetic proteins (BMPs) are a group of growth factors with dual functions in cancer development and progression. Recently, certain tumor-promoting roles have been identified for selected antagonists/inhibitors (BMPIs) of this developmental pathway. A recent focus on the implication of BMP in colorectal canc...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.04.004

    authors: Karagiannis GS,Treacy A,Messenger D,Grin A,Kirsch R,Riddell RH,Diamandis EP

    更新日期:2014-10-01 00:00:00

  • Glycan-related gene expression signatures in breast cancer subtypes; relation to survival.

    abstract::Alterations in glycan structures are early signs of malignancy and have recently been proposed to be in part a driving force behind malignant transformation. Here, we explore whether differences in expression of genes related to the process of glycosylation exist between breast carcinoma subtypes - and look for their ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.12.013

    authors: Potapenko IO,Lüders T,Russnes HG,Helland Å,Sørlie T,Kristensen VN,Nord S,Lingjærde OC,Børresen-Dale AL,Haakensen VD

    更新日期:2015-04-01 00:00:00

  • Activation of TNF-α/NF-κB axis enhances CRL4BDCAF11 E3 ligase activity and regulates cell cycle progression in human osteosarcoma cells.

    abstract::Cullin 4B, a member of the Cullins, which serve as scaffolds to facilitate the assembly of E3 ligase complexes, is aberrantly expressed in many cancers, including osteosarcoma. Recently, we observed that CUL4B forms the CRL4BDCAF11 E3 ligase, which specifically ubiquitinates and degrades the cyclin-dependent kinase (C...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12176

    authors: Zhang C,Chen B,Jiang K,Lao L,Shen H,Chen Z

    更新日期:2018-04-01 00:00:00

  • Inhibition of fucosylation in human invasive ductal carcinoma reduces E-selectin ligand expression, cell proliferation, and ERK1/2 and p38 MAPK activation.

    abstract::Breast cancer tissue overexpresses fucosylated glycans, such as sialyl-Lewis X/A (sLeX/A ), and α-1,3/4-fucosyltransferases (FUTs) in relation to increased disease progression and metastasis. These glycans in tumor circulating cells mediate binding to vascular E-selectin, initiating tumor extravasation. However, their...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12163

    authors: Carrascal MA,Silva M,Ramalho JS,Pen C,Martins M,Pascoal C,Amaral C,Serrano I,Oliveira MJ,Sackstein R,Videira PA

    更新日期:2018-05-01 00:00:00

  • Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.

    abstract::Pharmacogenomics is the study of genetic factors determining drug response or toxicity. The use of pharmacogenomics is especially desirable in oncology because the therapeutic index of oncology drugs is often narrow, the need for favorable drug response is often acute, and the consequences of drug toxicity can be life...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2012.01.005

    authors: O'Donnell PH,Ratain MJ

    更新日期:2012-04-01 00:00:00

  • Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer.

    abstract::Central nervous system (CNS) metastasis is one of the serious complications of epidermal growth factor receptor (EGFR)-mutant lung cancer, which arises due to poor penetration of the brain-blood barrier by EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Although osimertinib, a third-generation EGFR-TKI, has efficacy agai...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12394

    authors: Kim DH,Choi YJ,Sung KJ,Yoo SA,Sung YH,Kim JK,Choi CM,Yun M,Lee EY,Jin YS,Cook S,Rho JK,Lee JC

    更新日期:2018-12-01 00:00:00

  • In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor.

    abstract::The concept of polypharmacology involves the interaction of drug molecules with multiple molecular targets. It provides a unique opportunity for the repurposing of already-approved drugs to target key factors involved in human diseases. Herein, we used an in silico target prediction algorithm to investigate the mechan...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12810

    authors: Ariey-Bonnet J,Carrasco K,Le Grand M,Hoffer L,Betzi S,Feracci M,Tsvetkov P,Devred F,Collette Y,Morelli X,Ballester P,Pasquier E

    更新日期:2020-12-01 00:00:00

  • Pathway-based personalized analysis of breast cancer expression data.

    abstract:INTRODUCTION:Most analyses of high throughput cancer data represent tumors by "atomistic" single-gene properties. Pathifier, a recently introduced method, characterizes a tumor in terms of "coarse grained" pathway-based variables. METHODS:We applied Pathifier to study a very large dataset of 2000 breast cancer samples...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2015.04.006

    authors: Livshits A,Git A,Fuks G,Caldas C,Domany E

    更新日期:2015-08-01 00:00:00

  • Mining cancer gene expression databases for latent information on intronic microRNAs.

    abstract::Around 50% of all human microRNAs reside within introns of coding genes and are usually co-transcribed. Gene expression datasets, therefore, should contain a wealth of miRNA-relevant latent information, exploitable for many basic and translational research aims. The present study was undertaken to investigate this pos...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.10.001

    authors: Monterisi S,D'Ario G,Dama E,Rotmensz N,Confalonieri S,Tordonato C,Troglio F,Bertalot G,Maisonneuve P,Viale G,Nicassio F,Vecchi M,Di Fiore PP,Bianchi F

    更新日期:2015-02-01 00:00:00

  • Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.

    abstract::The small heat-shock protein of 27 kDa (HSP27) is highly expressed in many cancers and is associated with aggressive tumour behaviour, metastasis, poor prognosis and resistance to chemotherapy. We aimed at assessing the role of HSP27 in modulating responses to target therapies. We selected several oncogene-addicted ca...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12042

    authors: Konda JD,Olivero M,Musiani D,Lamba S,Di Renzo MF

    更新日期:2017-06-01 00:00:00

  • Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.

    abstract::Modern technologies enable detection and characterization of circulating tumor cells (CTC) in peripheral blood samples. Thus, CTC have attracted interest as markers for therapeutic response in breast cancer. First studies have incorporated CTC analyses to guide therapeutic interventions and stratification of breast ca...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2016.07.005

    authors: Gasch C,Oldopp T,Mauermann O,Gorges TM,Andreas A,Coith C,Müller V,Fehm T,Janni W,Pantel K,Riethdorf S

    更新日期:2016-10-01 00:00:00

  • Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.

    abstract::Platinum-based chemotherapy has been the cornerstone treatment for small cell lung cancer (SCLC) for decades, but no major progress has been made in the past 20 years with regard to overcoming chemoresistance. As the cell cycle checkpoint kinase 1 (Chk1) plays a key role in DNA damage response to chemotherapeutic drug...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12882

    authors: Zhao X,Kim IK,Kallakury B,Chahine JJ,Iwama E,Pierobon M,Petricoin E,McCutcheon JN,Zhang YW,Umemura S,Chen V,Wang C,Giaccone G

    更新日期:2020-12-15 00:00:00

  • Essential role of HDAC6 in the regulation of PD-L1 in melanoma.

    abstract::Histone deacetylases (HDACs), originally described as histone modifiers, have more recently been demonstrated to target a variety of other proteins unrelated to the chromatin environment. In this context, our present work demonstrates that the pharmacological or genetic abrogation of HDAC6 in primary melanoma samples ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2015.12.012

    authors: M L,P PV,T K,M P,E S,J P,K V W,C L,F C,S D,M SKS,M M,A K,J PI,A S,E S,J W,E M S,A V

    更新日期:2016-05-01 00:00:00

  • Quality-assured research environments for translational cancer research.

    abstract::In order to secure high-quality cancer care for increasing numbers of cancer patients in the upcoming decades, the complete continuum of cancer research and cancer care needs a thorough overhaul, with more emphasis on prevention and early detection, and a greater focus on the development of innovative treatments that ...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1002/1878-0261.12441

    authors: Berns A

    更新日期:2019-03-01 00:00:00

  • Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate.

    abstract::GPNMB is a melanoma-associated glycoprotein that is targeted by the CR011-vcMMAE antibody-drug conjugate (ADC). Previous studies have shown that CR011-vcMMAE induces the apoptosis of GPNMB-expressing tumor cells in vitro and tumor regression in xenograft models. This ADC is currently in clinical trials for melanoma. I...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2008.02.002

    authors: Qian X,Mills E,Torgov M,LaRochelle WJ,Jeffers M

    更新日期:2008-06-01 00:00:00

  • Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.

    abstract::The presence of circulating tumor cells (CTCs) in the blood of ovarian cancer patients was shown to correlate with decreased overall survival, whereby CTCs with epithelial-mesenchymal-transition (EMT) or stem-like traits are supposed to be involved in metastatic progression and recurrence. Thus, investigating the tran...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2016.04.002

    authors: Blassl C,Kuhlmann JD,Webers A,Wimberger P,Fehm T,Neubauer H

    更新日期:2016-08-01 00:00:00

  • Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility - a prospective, translational study.

    abstract::Glioblastoma (GBM) is an incurable brain tumor for which new treatment strategies are urgently needed. Next-generation sequencing of GBM has most often been performed retrospectively and on archival tissue from both diagnostic and relapse surgeries with limited knowledge of clinical information, including treatment gi...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12790

    authors: Nørøxe DS,Yde CW,Østrup O,Michaelsen SR,Schmidt AY,Kinalis S,Torp MH,Skjøth-Rasmussen J,Brennum J,Hamerlik P,Poulsen HS,Nielsen FC,Lassen U

    更新日期:2020-09-04 00:00:00

  • Regulation of the localisation and function of the oncogene LYRIC/AEG-1 by ubiquitination at K486 and K491.

    abstract::The pivotal role of LYRIC/AEG-1 in malignant transformation, tumourigenesis and chemo-resistance has previously been demonstrated in different cell types and sub-cellular compartments. The localisation of LYRIC/AEG-1 appears crucial to its function and is regulated by three lysine-rich nuclear localisation signal regi...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.01.009

    authors: Luxton HJ,Barnouin K,Kelly G,Hanrahan S,Totty N,Neal DE,Whitaker HC

    更新日期:2014-05-01 00:00:00

  • Translational cancer research - a coherent cancer research continuum.

    abstract::The main components of the cancer research continuum are basic/preclinical research, early and late clinical research and, after the adoption of an innovation by the healthcare or health organisations, outcomes research. Translational cancer research, defined as a coherent cancer research continuum, is mandatory to ad...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1002/1878-0261.12450

    authors: Ringborg U

    更新日期:2019-03-01 00:00:00

  • Molecular genomic features associated with in vitro response of the NCI-60 cancer cell line panel to natural products.

    abstract::Natural products remain a significant source of anticancer chemotherapeutics. The search for targeted drugs for cancer treatment includes consideration of natural products, which may provide new opportunities for antitumor cytotoxicity as single agents or in combination therapy. We examined the association of molecula...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12849

    authors: Krushkal J,Negi S,Yee LM,Evans JR,Grkovic T,Palmisano A,Fang J,Sankaran H,McShane LM,Zhao Y,O'Keefe BR

    更新日期:2020-11-09 00:00:00

  • Hepatocellular carcinoma: Where there is unmet need.

    abstract::Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor most commonly associated with underlying chronic liver disease, especially hepatitis. It is a growing problem in the United States and worldwide. There are two potential ways to prevent HCC. Primary prevention which is based on vaccination or secondar...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2015.06.005

    authors: Bupathi M,Kaseb A,Meric-Bernstam F,Naing A

    更新日期:2015-10-01 00:00:00

  • Honokiol confers immunogenicity by dictating calreticulin exposure, activating ER stress and inhibiting epithelial-to-mesenchymal transition.

    abstract::Peritoneal dissemination is a major clinical obstacle in gastrointestinal cancer therapy, and it accounts for the majority of cancer-related mortality. Calreticulin (CRT) is over-expressed in gastric tumors and has been linked to poor prognosis. In this study, immunohistochemistry studies revealed that the up-regulati...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.12.009

    authors: Liu SH,Lee WJ,Lai DW,Wu SM,Liu CY,Tien HR,Chiu CS,Peng YC,Jan YJ,Chao TH,Pan HC,Sheu ML

    更新日期:2015-04-01 00:00:00

  • Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?

    abstract::Histone methyltransferases (HMTs) catalyze the methylation of lysine and arginine residues on histone tails and non-histone targets. These important post-translational modifications are exquisitely regulated and affect chromatin compaction and transcriptional programs leading to diverse biological outcomes. There is a...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2016.09.003

    authors: Michalak EM,Visvader JE

    更新日期:2016-12-01 00:00:00

  • Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.

    abstract::Vestibular schwannomas (VSs), the most common tumors of the cerebellopontine angle, arise from Schwann cells lining the vestibular nerve. Pharmacotherapies against VS are almost non-existent. Although the therapeutic inhibition of inflammatory modulators has been established for other neoplasms, it has not been explor...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2015.03.009

    authors: Dilwali S,Briët MC,Kao SY,Fujita T,Landegger LD,Platt MP,Stankovic KM

    更新日期:2015-08-01 00:00:00

  • Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS).

    abstract:PURPOSE:DNA analysis by NGS has become important to direct the clinical care of cancer patients. However, NGS is not successful in all cases, and the factors responsible for test failures have not been systematically evaluated. MATERIALS AND METHODS:A series of 1528 solid and hematolymphoid tumor specimens was tested ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2015.05.004

    authors: Al-Kateb H,Nguyen TT,Steger-May K,Pfeifer JD

    更新日期:2015-11-01 00:00:00

  • The metastasis-associated molecule C4.4A promotes tissue invasion and anchorage independence by associating with the alpha6beta4 integrin.

    abstract::C4.4A is a metastasis-associated molecule that functions appear to rely on associated alph6beta4 integrin. To corroborate the impact of the C4.4A-alpha6beta4 integrin association on metastasis formation, C4.4A was knocked-down in a highly metastatic rat pancreatic adenocarcinoma (ASML, ASML-C4.4Akd). Metastasis format...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2013.05.002

    authors: Thuma F,Ngora H,Zöller M

    更新日期:2013-10-01 00:00:00

  • Integrative analysis of cancer imaging readouts by networks.

    abstract::Cancer is a multifactorial and heterogeneous disease. The corresponding complexity appears at multiple levels: from the molecular and the cellular constitution to the macroscopic phenotype, and at the diagnostic and therapeutic management stages. The overall complexity can be approximated to a certain extent, e.g. cha...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2014.08.013

    authors: Dominietto M,Tsinoremas N,Capobianco E

    更新日期:2015-01-01 00:00:00

  • miR-367 as a therapeutic target in stem-like cells from embryonal central nervous system tumors.

    abstract::Aberrant expression of the pluripotency factor OCT4A in embryonal tumors of the central nervous system (CNS) is a key factor that contributes to tumor aggressiveness and correlates with poor patient survival. OCT4A overexpression has been shown to up-regulate miR-367, a microRNA (miRNA) that regulates pluripotency in ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12562

    authors: Kaid C,Jordan D,Bueno HMS,Araujo BHS,Assoni A,Okamoto OK

    更新日期:2019-12-01 00:00:00

  • Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.

    abstract::Molecular characterization of cancers is important in dictating prognostic factors and directing therapy. Next-generation sequencing of plasma circulating tumor DNA (ctDNA) offers less invasive, more convenient collection, and a more real-time representation of a tumor and its molecular heterogeneity than tissue. Howe...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12791

    authors: Charo LM,Eskander RN,Okamura R,Patel SP,Nikanjam M,Lanman RB,Piccioni DE,Kato S,McHale MT,Kurzrock R

    更新日期:2021-01-01 00:00:00

  • PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.

    abstract::Triple negative breast cancer (TNBC) is a very aggressive subgroup of breast carcinoma, still lacking specific markers for an effective targeted therapy and with a poorer prognosis compared to other breast cancer subtypes. In this study we investigated the possibility that TNBC cells contribute to the establishment of...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.03.015

    authors: Plantamura I,Casalini P,Dugnani E,Sasso M,D'Ippolito E,Tortoreto M,Cacciatore M,Guarnotta C,Ghirelli C,Barajon I,Bianchi F,Triulzi T,Agresti R,Balsari A,Campiglio M,Tripodo C,Iorio MV,Tagliabue E

    更新日期:2014-07-01 00:00:00